345 related articles for article (PubMed ID: 27743957)
21. The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands.
van der Heiden-van der Loo M; Siesling S; Wouters MW; van Dalen T; Rutgers EJ; Peeters PH
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S522-8. PubMed ID: 25986872
[TBL] [Abstract][Full Text] [Related]
22. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy.
Wickberg Å; Magnuson A; Holmberg L; Adami HO; Liljegren G
Breast; 2018 Dec; 42():54-60. PubMed ID: 30176553
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
24. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype.
McGuire A; Lowery AJ; Kell MR; Kerin MJ; Sweeney KJ
Ann Surg Oncol; 2017 Oct; 24(11):3124-3132. PubMed ID: 28755141
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
26. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
28. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group.
Hannoun-Levi JM; Resch A; Gal J; Kauer-Dorner D; Strnad V; Niehoff P; Loessl K; Kovács G; Van Limbergen E; Polgár C;
Radiother Oncol; 2013 Aug; 108(2):226-31. PubMed ID: 23647758
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation.
Lv Y; He L; Wang C; Zhang L; Zhang B; Song Y
Medicine (Baltimore); 2019 Feb; 98(6):e14407. PubMed ID: 30732191
[TBL] [Abstract][Full Text] [Related]
31. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
33. Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand.
Kongsiang A; Tangvoraphonkchai V; Jirapornkul C; Promthet S; Kamsa-Ard S; Suwanrungruang K
Asian Pac J Cancer Prev; 2014; 15(23):10505-8. PubMed ID: 25556500
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry.
Gabani P; Cyr AE; Zoberi JE; Ochoa LL; Matesa MA; Thomas MA; Garcia J; Margenthaler JA; Naughton MJ; Ma C; Sanati S; Zoberi I
Brachytherapy; 2018; 17(1):171-180. PubMed ID: 29089275
[TBL] [Abstract][Full Text] [Related]
35. Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer.
Chatzikonstantinou G; Strouthos I; Scherf C; Köhn J; Solbach C; Rödel C; Tselis N
J Radiat Res; 2021 May; 62(3):465-472. PubMed ID: 33604659
[TBL] [Abstract][Full Text] [Related]
36. Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015.
Stuart-Harris R; Dahlstrom JE; Gupta R; Zhang Y; Craft P; Shadbolt B
Breast; 2019 Apr; 44():153-159. PubMed ID: 30785024
[TBL] [Abstract][Full Text] [Related]
37. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
39. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
40. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
